All stock lists
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
70.03+1.83 (+2.68%)
Insider Score
––Not scored
TARS Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
Financial Health Score
Sound
From TARS’s reported statements · Q2 2026 (trailing 12 months)
Profitability6 / 20
Loses money on what it sells.
- Revenue
- $606.3M
- Net income
- -$46.5M
- Net margin
- -7.7%
Leverage17 / 20
Little or no net debt.
- Total debt
- $88.7M
- Cash
- $204.6M
- Debt / equity
- 0.26
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $562.0M
- Current liabilities
- $175.8M
- Current ratio
- 3.20
Cash generation17 / 20
The business funds itself from operations.
- Operating cash flow
- $79.7M
- Free cash flow
- $61.5M
- FCF margin
- 10.2%
Dilution & runway18 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 43.4M
- Share growth (1y)
- 2.4%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
TARS Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 173.91 M | 162.05 M | 151.67 M | 118.70 M | 102.66 M | 78.33 M |
| Revenue Growth (YoY) | 69.41 % | 106.87 % | 128.39 % | 146.68 % | 151.54 % | 183.68 % |
| Cost of Revenue | 12.11 M | 9.40 M | 10.93 M | 24.59 M | 6.24 M | 5.21 M |
| Gross Profit | 161.80 M | 152.66 M | 140.74 M | 94.10 M | 96.42 M | 73.12 M |
| SG&A Expense | 150.70 M | 136.43 M | 130.68 M | 108.63 M | 103.01 M | 85.00 M |
| R&D Expense | 31.01 M | 22.35 M | 18.04 M | 16.28 M | 15.59 M | 14.41 M |
| Operating Expenses | 181.71 M | 158.78 M | 148.72 M | 108.63 M | 118.61 M | 99.40 M |
| Operating Income | -19.91 M | -6.12 M | -7.98 M | -14.53 M | -22.18 M | -26.28 M |
| Pretax Income | -15.84 M | -9.32 M | -6.31 M | -12.59 M | -20.34 M | -25.12 M |
| Tax Provision | 2.72 M | -2.35 M | 2.06 M | 0.00 | 0.00 | 0.00 |
| Net Income | -18.55 M | -6.97 M | -8.37 M | -12.59 M | -20.34 M | -25.12 M |
| EPS (Basic) | -0.43 | -0.16 | -0.20 | -0.30 | -0.48 | -0.64 |
| EPS (Diluted) | -0.43 | -0.16 | -0.20 | -0.30 | -0.48 | -0.64 |
| Shares Outstanding | 43.39 M | 42.96 M | 42.78 M | 42.61 M | 42.36 M | 39.35 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.